Previous research has demonstrated that the density of tumour-infiltrating T cells can serve as a prognostic marker in atypical meningiomas, and CD3 + and CD8 + expression levels play a critical role in the selection of potential T-cell-based immunotherapies [56, 57]. This evidence concerns the gene CD8A and meningioma.